Mega Matrix Inc. Announces 2024 Year-End Financial Results
SINGAPORE, March 27, 2025 /PRNewswire/ -- Mega Matrix Inc. ("MPU" or the "Company") (NYSE American: MPU), today announced year-end financial results for its fiscal year 2024 ended December 31, 2024. Financial Highlights In 2024, the Company's total...
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
Financial Performance: Strong Year-over-Year Improvemen t - Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income. - Net Loss Reduction: 71.5% year-over-year improvement. Key Product Advancements - Sugemalimab...
DPC Dash Ltd Announces Full Year 2024 Financial Results
Revenues increased to RMB4.31 billion, representing 41.4% year-over-year growth Store-level operating profit grew by 48.7%; Adjusted group EBITDA increased by 64.1% Adjusted net profit reached RMB131.2 million, representing 1,394.2% year-over-year...
Xuan Wu Cloud Announces 2024 Annual Results
Achieving a turnaround from loss to profit year-on-year, and committing to high-quality business development with focus on AI + SaaS Net profit attributable to the owners of the Company reached RMB6.9 million, achieving a turnaround from loss to...
GIGABYTE Announces AORUS SUPREME 5 High-End Pre-Built Gaming PC Now Available in North America
TAIPEI, March 26, 2025 /PRNewswire/ -- The world's leading computer brand, GIGABYTE, is bringing its high-performance pre-built gaming PC, AORUS SUPREME 5, to the North American market. Designed for gamers and power users seeking seamless...
Sniffer Robotics Announces International Partnership to Meet Demand for Methane Detection
Made possible by the roll-out of the SnifferDRONE™ CH4 Gen II Drone ANN ARBOR, Mich., March 26, 2025 /PRNewswire/ -- Sniffer Robotics expanded its presence into South America through a strategic partnership with Argentina-based BRa Tecnologia...
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland, March 26, 2025 /PRNewswire/ -- Vaximm AG, a...
Fosun Pharma Announces 2024 Annual Results
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 26, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code:...
vivo Announces Robotics Lab and Showcases its First Mixed Reality Headset at the Boao Forum 2025
SHENZHEN, China, March 25, 2025 /PRNewswire/ -- Today, the Boao Forum for Asia Annual Conference 2025 commenced in Boao, Hainan. As a strategic partner of the event for the fourth consecutive year and a new member of the Boao Forum for Asia Board of...
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
BEIJING, March 24, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has...